Reference : Clinical added-value of 18FDG PET in neuroendocrine-Merkel cell carcinoma
Scientific journals : Article
Human health sciences : Oncology
Clinical added-value of 18FDG PET in neuroendocrine-Merkel cell carcinoma
Belhocine, Tarik [> > > >]
Pierard, Gérald mailto [Université de Liège – ULg > Département des sciences cliniques > Dermatopathologie >]
Frühling, Janos [> > > >]
Letesson, Gaëtan [> > > >]
Bolle, Stéphanie [> > > >]
Hustinx, Roland mailto [Université de Liège - ULg > Département des sciences cliniques > Médecine nucléaire]
Dargent, Jean-Louis [> > > >]
Flamen, Patrick [> > > >]
Rigo, Pierre mailto [Université de Liège - ULg > Département des sciences de la motricité > Pathologie générale et médecine nucléaire >]
Oncology Reports
DA Spandidos
Yes (verified by ORBi)
[en] Merkel cell carcinoma ; (18)FDG PET ; PET-CT ; neuroendocrine tumor
[en] Merkel cell carcinoma (MCC) is a rare and highly malignant skin cancer with neuroendocrine differentiation. We studied the potential value of (18)FDG PET in the management of MCC. Eleven patients with MCC were examined by (18)FDG PET and PET-CT for staging purpose (n=4) or for detection of recurrence (n=7). Qualitative and quantitative interpretation of PET studies was performed routinely. (18)FDG PET observations were compared to clinical and radiological findings. In 6 patients, PET findings were also compared to histology. In 7 patients, the (18)FDG tumor uptake was compared to the MCC proliferative activity expressed by the Ki-67 index. (18)FDG PET was contributive in 10/11 MCC patients. In 7 patients, (18)FDG PET detected focal lesions or a disseminated stage of the disease including dermal, nodal and visceral metastases. In 3 patients, a normal (18)FDG PET confirmed complete remission of disease. Most MCC patients exhibited highly (18)FDG-avid sites suggestive of increased glucose metabolism. This imaging pattern was related to a high proliferative activity (Ki-67 index > 50%). In 1 patient with a weakly proliferative nodal MCC (Ki-67 < 10%), a false negative result was yielded by metabolic imaging. In 4/11 patients, (18)FDG PET revealed an unsuspected second neoplasm in addition to MCC. It is concluded that whole-body (18)FDG PET may be useful in the management of MCC patients. However, a normal (18)FDG PET aspect cannot rule out MCC with low proliferative activity.

File(s) associated to this reference

Fulltext file(s):

Restricted access
Belhocine et al, Oncology Reports, 2006.pdfNo commentaryPublisher postprint231.12 kBRequest copy

Bookmark and Share SFX Query

All documents in ORBi are protected by a user license.